Testing IBI351 with chemotherapy for KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung cancer that is not squamous type (non-squamous NSCLC) and it has a KRAS G12C mutation
- Your cancer is advanced and cannot be surgically removed or has spread (metastatic)
- Your blood counts, liver, and kidney function are adequate for study treatment
- You have not had chemotherapy or other anti-cancer medicines for advanced/metastatic non-squamous NSCLC before
- You can take oral medicines (and you don’t have major stomach surgery or serious bowel/stomach problems that block oral dosing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with advanced or spreading non-small cell lung cancer that has a KRAS G12C mutation, who have already taken the drug IBI-351. It aims to understand how well this drug works in everyday practice and why it might help you.
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hear when a new Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.